Immunocore generated $104478000 in Q4 2025 revenue from KIMMTRAK, reflecting continued growth year-over-year, while net loss widened to $30060000 due to increased R&D investment and ongoing Phase 3 trials.

Immunocore announced robust second quarter 2025 financial results, with KIMMTRAK net product sales reaching $98.0 million, a 30% year-over-year increase. The company reported a net loss of $10.3 million and a loss per share of $0.20, showing an improvement compared to the same period last year. Significant progress was made in advancing its Phase 3 trials for TEBE-AM and PRISM-MEL-301, alongside the expansion of KIMMTRAK's global reach.

Immunocore reported strong financial performance in the first quarter of 2025, driven by significant growth in KIMMTRAK net product sales. The company achieved profitability for the quarter and maintained a strong cash position to support ongoing clinical development programs.

Immunocore reported Q4 2024 financial results, highlighted by $84.1 million in KIMMTRAK net sales. The company progressed its clinical pipeline and expanded into autoimmune diseases, supported by a strong cash position.

Immunocore reported a strong third quarter with KIMMTRAK net revenues of $80.2 million, a 28% increase over 3Q 2023. The company also reported positive net income and advanced its pipeline with ongoing Phase 3 trials and presentations of clinical data.

Immunocore reported net product sales of $75.3 million for the second quarter of 2024, driven by growth in the US. The company is progressing its clinical trials, including the registrational Phase 3 TEBE-AM trial and the Phase 3 PRISM-MEL-301 trial. Immunocore is also expanding its platform into autoimmune diseases.

Immunocore reported a 36% increase in KIMMTRAK net product revenue, reaching $70.3 million in Q1 2024. The company continues to expand global access and advance clinical trials for its pipeline candidates, including brenetafusp. Net loss for the quarter was $24.4 million, and cash and cash equivalents stood at $832.8 million.

Immunocore reported Q4 2023 financial results with KIMMTRAK net revenues reaching $67.6 million and a net loss of $19.7 million. The company is advancing its clinical trials, including a collaboration with Bristol Myers Squibb. Cash and cash equivalents stood at $442.6 million as of December 31, 2023, with additional funds raised in February 2024.